Astaxanthin for Healthy Subjects (HS)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
SGS Stephens, Inc, Richardson, TX
Healthy Subjects (HS)
Astaxanthin - DietarySupplement
Eligibility
18 - 65
Female
What conditions do you have?
Select

Study Summary

Astaxanthin is recognized as a bioactive compound with potential benefits for human health. This study aims to evaluate a specific nutritional supplement impact on markers of oxidative stress, inflammation, lipid levels, blood flow, visual skin markers, measures of longevity, mood and skin condition.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: 4 and 12 weeks

12 weeks
To assess the effect of the Astaxanthin on measures of longevity within the group and compared to placebo
To assess the effect of the Astaxanthin on visual skin markers (wrinkles, pores, visible spots, tonality (complexion - even skin tone), pigmentation, roughness (texture), UV porphyrins) after 12 weeks within the group and compared to placebo
4 and 12 weeks
To assess the effect of Astaxanthin on oxidative stress within the group and compared to placebo
To assess the effect of the Astaxanthin on blood flow within the group and compared to placebo
To assess the effect of the Astaxanthin on facial skin hydration within the group and compared to placebo
To assess the effect of the Astaxanthin on inflammation within the group and compared to placebo
To assess the effect of the Astaxanthin on lipid levels within the group and compared to placebo
To assess the effect of the Astaxanthin on participant reported facial skin satisfaction within the group and compared to placebo
To assess the effect of the Astaxanthin on participant reported mood states within the group and compared to placebo
Over 12 weeks
To assess the safety and tolerability of the Astaxanthin in healthy participants

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Astaxanthin
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

60 Total Participants · 2 Treatment Groups

Primary Treatment: Astaxanthin · Has Placebo Group · N/A

Astaxanthin
DietarySupplement
Experimental Group · 1 Intervention: Astaxanthin · Intervention Types: DietarySupplement
Placebo
Other
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Astaxanthin
2014
Completed Phase 3
~270

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4 and 12 weeks
Closest Location: SGS Stephens, Inc · Richardson, TX
Photo of texas 1Photo of texas 2Photo of texas 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Healthy Subjects (HS)
0 CompletedClinical Trials

Who is running the clinical trial?

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.NETWORK
26 Previous Clinical Trials
1,479 Total Patients Enrolled
11 Trials studying Healthy Subjects (HS)
559 Patients Enrolled for Healthy Subjects (HS)
LycoRed Ltd.Lead Sponsor
12 Previous Clinical Trials
640 Total Patients Enrolled
Shoná Burkes-Henderson, PhDPrincipal InvestigatorSGS Stephens, Inc

Eligibility Criteria

Age 18 - 65 · Female Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a body mass index between 18.0 and 34.9 lbs/in2 (inclusive).
You are in good general health.
You are willing to change your diet or lifestyle significantly for the duration of the study.
You are willing and able to agree to the requirements and restrictions of this study, willing to give voluntary consent, able to understand and read the questionnaires, able to carry out all study related procedures, and agree to allow all study related evaluations.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.